ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cetuximab

Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Neoplasms, led by 26 companies.

Drug pageCetuximab: every studyMany companies study it; this page follows only the 90 they lead. All 565 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 4, 200390 company-led studies, 13 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only300 open or runningphase 3since Jun 4, 2003Apr 30, 2002none ahead
Merck KGaA, Darmstadt, Germanyits history only170 open or runningphase 3since Sep 7, 2005Jul 28, 2005none ahead
Pfizerits history only53 open or runningphase 3since Oct 5, 2020Dec 1, 2010Dec 31, 2029phase 2 · NCT05226871
Bristol-Myers Squibbits history only40 open or runningphase 3since Nov 17, 2017Jan 7, 2008none ahead
Hoffmann-La Rocheits history only41 open or runningphase 2since Dec 18, 2007Jul 3, 2007Aug 31, 2030phase 1 · NCT04929223
R-Pharmits history only40 open or runningphase 3since Feb 20, 2026Sep 28, 2006none ahead
Sarah Cannon Research Instituteits history only41 open or runningphase 3since Nov 9, 2005Nov 2, 2005none ahead
Merckits history only22 open or runningphase 3since May 21, 2025May 21, 2025Mar 28, 2029phase 3 · NCT06997497
Novartisits history only20 open or runningphase 2since May 16, 2012May 24, 2007none ahead
Pierre Fabreits history only20 open or runningphase 2since Sep 17, 2018Sep 17, 2018none ahead
Innate Pharma10 open or runningphase 2since Dec 17, 2015Dec 17, 2015none ahead

Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, Prologue Research International, Sanofi and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Innate Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2015First study: phase 2 study in Head and Neck NeoplasmsFirst studyNCT02643550 · 143 enrolled · United States, France
  2. Dec 9, 2018Named cetuximabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, RPH-002

TargetBeta

EGFR →read by rule
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

The one study Innate Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02643550Head and Neck Neoplasms · United States, France2CompletedMar 28, 2023143

How it is read

Names in the registry

  • “Cetuximab”, 57 entries
  • “cetuximab”, 11 entries
  • “RPH-002”, 2 entries
  • “Cetuximab + Irinotecan”, 2 entries
  • “Cetuximab + mFOLFOX6”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.